Related Experiment Video

Updated: Jun 14, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.1K

Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma

Etienne Leveille1, Shalin Kothari1, Kadriye N Cosgun1

  • 1Center of Molecular and Cellular Oncology, Yale University, New Haven, Connecticut.

Cancer Discovery
|September 4, 2024
PubMed

Insights

New findings reveal why some diffuse large B-cell lymphoma patients don't respond to polatuzumab vedotin. Mechanisms include reduced CD79B accessibility and lower CD79B expression, impacting treatment effectiveness.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Polatuzumab vedotin offers a novel first-line therapy for diffuse large B-cell lymphoma (DLBCL).
  • Understanding resistance mechanisms is crucial for optimizing treatment outcomes.
  • Factors influencing patient response to polatuzumab vedotin are not fully elucidated.

Purpose of the Study:

  • To identify key biological mechanisms underlying reduced sensitivity to polatuzumab vedotin in DLBCL.
  • To elucidate the molecular players involved in resistance to CD79B-targeted therapy.

Main Methods:

  • Investigated the role of N-linked glycosylation in CD79B epitope accessibility.
  • Assessed the impact of KLHL6 E3 ligase activity on CD79B surface expression levels.
  • Utilized molecular and cellular assays to analyze drug sensitivity.

Main Results:

  • Reduced accessibility of the CD79B epitope, caused by N-linked glycosylation, was identified as a resistance mechanism.
  • Lower CD79B surface expression, driven by KLHL6 E3 ligase activity, also contributes to insensitivity.
  • These factors collectively impair the efficacy of polatuzumab vedotin.

Conclusions:

  • N-linked glycosylation of CD79B and KLHL6-mediated CD79B downregulation are critical determinants of polatuzumab vedotin response.
  • These findings provide insights into resistance mechanisms and potential therapeutic strategies for DLBCL.

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K